Bortezomib is a drug owned by Maia Pharmaceuticals Inc. It is protected by 3 US drug patents filed from 2023 to 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 23, 2042. Details of Bortezomib's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12005069 | Bortezomib compositions |
Sep, 2042
(17 years from now) | Active |
| US11752164 | Bortezomib compositions |
Sep, 2042
(17 years from now) | Active |
| US11679119 | Bortezomib compositions |
Sep, 2042
(17 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Bortezomib's patents.
Latest Legal Activities on Bortezomib's Patents
Given below is the list of recent legal activities going on the following patents of Bortezomib.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent eGrant Notification | 12 Sep, 2023 | US11752164 |
| Patent Issue Date Used in PTA Calculation Critical | 12 Sep, 2023 | US11752164 |
| Recordation of Patent eGrant | 12 Sep, 2023 | US11752164 |
| Recordation of Patent Grant Mailed Critical | 12 Sep, 2023 | US11752164 |
| Mail Patent eGrant Notification | 12 Sep, 2023 | US11752164 |
| Email Notification Critical | 12 Sep, 2023 | US11752164 |
| Email Notification Critical | 24 Aug, 2023 | US11752164 |
| Issue Notification Mailed Critical | 23 Aug, 2023 | US11752164 |
| Electronic Review Critical | 10 Aug, 2023 | US11752164 |
| Email Notification Critical | 10 Aug, 2023 | US11752164 |
US patents provide insights into the exclusivity only within the United States, but Bortezomib is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Bortezomib's family patents as well as insights into ongoing legal events on those patents.
Bortezomib's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Bortezomib's generic launch date based on the expiry of its last outstanding patent is estimated to be Sep 23, 2042 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Bortezomib Generic API suppliers:
Bortezomib is the generic name for the brand Bortezomib. 19 different companies have already filed for the generic of Bortezomib, with Accord Hlthcare having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Bortezomib's generic
Alternative Brands for Bortezomib
Bortezomib which is used for treating adult patients with multiple myeloma., has several other brand drugs using the same active ingredient (Bortezomib). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Takeda Pharms Usa |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Bortezomib, Bortezomib's active ingredient. Check the complete list of approved generic manufacturers for Bortezomib
About Bortezomib
Bortezomib is a drug owned by Maia Pharmaceuticals Inc. It is used for treating adult patients with multiple myeloma. Bortezomib uses Bortezomib as an active ingredient. Bortezomib was launched by Maia Pharms Inc in 2022.
Approval Date:
Bortezomib was approved by FDA for market use on 27 July, 2022.
Active Ingredient:
Bortezomib uses Bortezomib as the active ingredient. Check out other Drugs and Companies using Bortezomib ingredient
Treatment:
Bortezomib is used for treating adult patients with multiple myeloma.
Dosage:
Bortezomib is available in solution form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 3.5MG/1.4ML (2.5MG/ML) | SOLUTION | Discontinued | INTRAVENOUS |
| 3.5MG/3.5ML (1MG/ML) | SOLUTION | Discontinued | INTRAVENOUS |
Bortezomib is a drug owned by Fresenius Kabi Usa Llc. It is protected by 1 US drug patent filed in 2018 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Nov 03, 2032. Details of Bortezomib's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US8962572 | Bortezomib formulations |
Nov, 2032
(7 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Bortezomib's patents.
Latest Legal Activities on Bortezomib's Patents
Given below is the list of recent legal activities going on the following patents of Bortezomib.
| Activity | Date | Patent Number |
|---|---|---|
| | ||
| Patent eGrant Notification | 12 Sep, 2023 | US11752164 |
| Patent Issue Date Used in PTA Calculation Critical | 12 Sep, 2023 | US11752164 |
| Recordation of Patent eGrant | 12 Sep, 2023 | US11752164 |
| Recordation of Patent Grant Mailed Critical | 12 Sep, 2023 | US11752164 |
| Mail Patent eGrant Notification | 12 Sep, 2023 | US11752164 |
| Email Notification Critical | 12 Sep, 2023 | US11752164 |
| Email Notification Critical | 24 Aug, 2023 | US11752164 |
| Issue Notification Mailed Critical | 23 Aug, 2023 | US11752164 |
| Electronic Review Critical | 10 Aug, 2023 | US11752164 |
| Email Notification Critical | 10 Aug, 2023 | US11752164 |
US patents provide insights into the exclusivity only within the United States, but Bortezomib is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Bortezomib's family patents as well as insights into ongoing legal events on those patents.
Bortezomib's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Bortezomib's generic launch date based on the expiry of its last outstanding patent is estimated to be Nov 03, 2032 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Bortezomib Generic API suppliers:
Bortezomib is the generic name for the brand Bortezomib. 19 different companies have already filed for the generic of Bortezomib, with Accord Hlthcare having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Bortezomib's generic
Alternative Brands for Bortezomib
Bortezomib which is used for treating adult patients with multiple myeloma., has several other brand drugs using the same active ingredient (Bortezomib). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Takeda Pharms Usa |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Bortezomib, Bortezomib's active ingredient. Check the complete list of approved generic manufacturers for Bortezomib
About Bortezomib
Bortezomib is a drug owned by Fresenius Kabi Usa Llc. It is used for treating adult patients with multiple myeloma. Bortezomib uses Bortezomib as an active ingredient. Bortezomib was launched by Fresenius Kabi Usa in 2017.
Approval Date:
Bortezomib was approved by FDA for market use on 06 November, 2017.
Active Ingredient:
Bortezomib uses Bortezomib as the active ingredient. Check out other Drugs and Companies using Bortezomib ingredient
Treatment:
Bortezomib is used for treating adult patients with multiple myeloma.
Dosage:
Bortezomib is available in powder form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 3.5MG/VIAL | POWDER | Discontinued | INTRAVENOUS |